Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity

作者
Donglin Zeng,Jean Pan,Kuolung Hu,Eric Chi,Danyu Y. Lin
出处
期刊:Journal of Biopharmaceutical Statistics [Taylor & Francis]
卷期号:28 (2): 320-332 被引量:9
标识
DOI:10.1080/10543406.2017.1397012
摘要

To improve patients' access to safe and effective biological medicines, abbreviated licensure pathways for biosimilar and interchangeable biological products have been established in the US, Europe, and other countries around the world. The US Food and Drug Administration and European Medicines Agency have published various guidance documents on the development and approval of biosimilars, which recommend a "totality-of-the-evidence" approach with a stepwise process to demonstrate biosimilarity. The approach relies on comprehensive comparability studies ranging from analytical and nonclinical studies to clinical pharmacokinetic/pharmacodynamic (PK/PD) and efficacy studies. A clinical efficacy study may be necessary to address residual uncertainty about the biosimilarity of the proposed product to the reference product and support a demonstration that there are no clinically meaningful differences. In this article, we propose a statistical strategy that takes into account the similarity evidence from analytical assessments and PK studies in the design and analysis of the clinical efficacy study in order to address residual uncertainty and enhance statistical power and precision. We assume that if the proposed biosimilar product and the reference product are shown to be highly similar with respect to the analytical and PK parameters, then they should also be similar with respect to the efficacy parameters. We show that the proposed methods provide correct control of the type I error and improve the power and precision of the efficacy study upon the standard analysis that disregards the prior evidence. We confirm and illustrate the theoretical results through simulation studies based on the biosimilars development experience of many different products.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
等待断秋完成签到,获得积分10
刚刚
arsheng完成签到,获得积分10
1秒前
wtian1221完成签到,获得积分10
2秒前
wzz发布了新的文献求助10
2秒前
Extreme_jiang完成签到 ,获得积分10
3秒前
凶狠的擎宇完成签到 ,获得积分10
3秒前
张笨笨完成签到 ,获得积分10
4秒前
不战则已战必胜矣完成签到,获得积分10
4秒前
冷静芷雪完成签到,获得积分10
5秒前
ppp发布了新的文献求助10
6秒前
昏睡的妙梦完成签到,获得积分10
6秒前
多半是只废兔子完成签到 ,获得积分10
6秒前
小伙子完成签到 ,获得积分10
7秒前
tianquanbi完成签到,获得积分10
7秒前
子琤完成签到 ,获得积分10
7秒前
LYZSh完成签到,获得积分10
9秒前
无辜忆丹发布了新的文献求助10
10秒前
锈雀完成签到,获得积分10
12秒前
starleo完成签到,获得积分10
12秒前
甜蜜阑悦完成签到,获得积分20
13秒前
李昱辰完成签到,获得积分10
13秒前
依霏完成签到,获得积分10
14秒前
dan完成签到,获得积分10
15秒前
15秒前
nanfeng完成签到 ,获得积分10
15秒前
Nidhogg完成签到,获得积分10
15秒前
zzzzz完成签到,获得积分10
16秒前
风飒飒完成签到 ,获得积分10
16秒前
双碳小王子完成签到,获得积分10
16秒前
飘逸沛柔完成签到,获得积分20
18秒前
惜梦完成签到 ,获得积分10
19秒前
123完成签到,获得积分0
20秒前
清秀的落雁完成签到,获得积分10
20秒前
追梦的小孩子完成签到,获得积分10
20秒前
Chavin完成签到,获得积分10
22秒前
yy发布了新的文献求助10
23秒前
无辜忆丹完成签到,获得积分10
24秒前
24秒前
Cyueue完成签到,获得积分10
24秒前
研友_nPxRRn完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923